<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853615</url>
  </required_header>
  <id_info>
    <org_study_id>EC 2119</org_study_id>
    <nct_id>NCT04853615</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?</brief_title>
  <official_title>Is SGLT2 Inhibitors a Better Prophylactic Agent Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? A Multicenter Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast&#xD;
      Acute Kidney Injury in diabetic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population of Study o Group 1 :&#xD;
&#xD;
        1. st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after&#xD;
           radiocontrast.&#xD;
&#xD;
           o Group 2 :&#xD;
&#xD;
        2. nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily&#xD;
&#xD;
           o Group 3 :&#xD;
&#xD;
        3. rd group will receive the SGLT2i empagliflosin 25 mg once daily&#xD;
&#xD;
           o Group 4 :&#xD;
&#xD;
        4. thwill receive allopurinol and empagliflosin.&#xD;
&#xD;
      Inclusion Criteria :&#xD;
&#xD;
      o Age: more than30years, diabetes,diabetic kidney disease,GFR: more than30ml/min/1.73m2&#xD;
&#xD;
      Exclusion Criteria :&#xD;
&#xD;
      o Diabetics Patients with GFR less than 30 mL/min/1.73 m2.&#xD;
&#xD;
      Sample Size ( number of participants included ) :&#xD;
&#xD;
      800 patients Fayoum University Faculty of Medicine Scientific Research Ethics Committee&#xD;
&#xD;
      Methodology in details :&#xD;
&#xD;
      The chosen patients will be randomly allocated to 4 equal groups that will receive their&#xD;
      prophylaxis for 48 hours before and 48 hours after the radiocontrast administration. Baseline&#xD;
      serum creatinine will be obtained 72 hours before the planned intervention and before&#xD;
      administration of any protective protocol and follow-up serum creatinine will be obtained 72&#xD;
      hours and 1 week after contrast administration. The first control group will receive normal&#xD;
      saline 10ml/kg over 6 hours before and 6 hours after radiocontrast. Saline should be given by&#xD;
      infusion pump to guarantee steady rate of infusion. 2nd group will receive allopurinol 300 mg&#xD;
      and linagliptin 5 mg once daily. 3rd group will receive the SGLT2i empagliflosin 25 mg once&#xD;
      daily, and the 4th will receive allopurinol and empagliflosin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SGLT2i proves protective effect</measure>
    <time_frame>72hours after contrast</time_frame>
    <description>SGLT2i shows protected the kidneys against contrast injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SGLT2i is non inferior to allopurinol</measure>
    <time_frame>72hours after contrast</time_frame>
    <description>SGLT2i showed noninferiorty whencompared to allopurinol</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>SGLT2i Kideny Protection Against Contrast in Diabetic Kidney</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>3rd group will receive the SGLT2i empagliflosin 25 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>4thwill receive allopurinol and empagliflosin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>PAtient will receive empagliflozin 25 mg daily</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>SGLT2 inhibitors</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The chosen patients will be randomly allocated to 4 equal groups that will receive their&#xD;
        prophylaxis for 48 hours before and 48 hours after the radiocontrast administration&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: more than30years, Diabetes, Diabetic kidney disease, GFR: more&#xD;
             than30ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetics Patients with GFR less than 30 mL/min/1.73 m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed A Hammad, MD</last_name>
    <phone>+201001574639</phone>
    <email>aah12@fayoum.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Fayed, MD</last_name>
    <email>dr.fayed@gmail.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelkawi Hammad</investigator_full_name>
    <investigator_title>Lecturer of internal medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

